longterm therapyThe results of the present investigation demonstrate that the use of single standard doses of S and M in combination provide greater protection against the obstructive consequences of isocapnic HV of frigid air more than either drug alone. Within 60 min of administration, M and S individually attenuated between 30% and 54% of the airflow limitation in the control trial, respectively; however, the mixture blunted 82%, indicating an additive effect. Since thermal events, particularly exercise-induced bron-chospasm (EIB), are real-world stimuli that can adversely influence the lives of virtually all patients with asthma information of this type, when appropriately validated, could ultimately prove to be of great clinical value.

(P-adrenergic agonists have been the treatment of choice for EIB for a considerable time. In the last 15 years, the therapeutic benefits of the antileukotriene agents in the treatment of this condition have been recognized. However, there are some subjects who have little response to leukotrienes. The comparative effectiveness of each type of drug was not examined until the past few years. All of the available data to date, including those reported herein, indicate that, on average, both classes of compounds offer statistically similar degrees of prophylaxis. It was not until the work of Coreno and associates, however, that the amounts and duration of treatment required to produce benefits have been addressed. These investigators showed that longterm therapy with leukotriene blockers was not essential and that single doses of either a 5-lipoxygenase inhibitor or a cysteinyl leukotriene 1 receptor antagonist initiated sustained effects. In their study, protection developed within 60 min of ingestion of the available agents, including M, and remained stable for 8 to 12 h. The present findings concur nicely with these results. In addition, Dempsey et al and Hui and Barnes, as also reported in the present investigation, reported that therapy with a mixture of S and M produced greater bronchodilatation than therapy with M alone. Finally, these two drugs have been shown to provide additive protection against other bronchoprovocations. Dempsey et al found that single doses of M and S, when administered together to asthmatic individuals, blunted challenges with adenosine monophosphate more than the individual compounds. New ideas, new thoughts, new investigations and new technologies are overcroweded the web world nowadays. All news that you need at Canadian health care website, these news will help you to find a way out from such a deadlock from which you cannot have found the way for a long time.